Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

Rhea-AI Summary

Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.

Positive

• VK2809's Phase 2 trial demonstrated statistically significant reductions in LDL-C and liver fat content compared to placebo.
• The company is advancing its drug VK0214 in a Phase 1b trial for X-linked adrenoleukodystrophy (X-ALD).
• Viking holds exclusive worldwide rights to five therapeutic programs.

Negative

• None.

SAN DIEGO, Oct. 27, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2021, after the market close on Wednesday, November 3, 2021.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 3, 2021.  To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 10, 2021 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID #10160763.  Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2021-on-november-3-2021-301409989.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics report its financial results for Q3 2021?

Viking Therapeutics will report its financial results for the third quarter of 2021 on November 3, 2021.

What is VKTX's recent clinical trial progress?

VKTX has progressed VK2809 into Phase 2b trials for NASH and reported significant results in reducing LDL-C and liver fat.

What time is the conference call for Viking Therapeutics Q3 results?

The conference call will be held at 4:30 p.m. ET on November 3, 2021.

What therapies is Viking Therapeutics developing?

Viking Therapeutics is developing VK2809 for metabolic disorders and VK0214 for X-ALD among other programs.